We serve Chemical Name:3-Amino-N,N-diethyl-4-methoxybenzenesulfonamide CAS:97-35-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Amino-N,N-diethyl-4-methoxybenzenesulfonamide
CAS.NO:97-35-8
Synonyms:2-Methoxy-5-(diethylsulfamoyl)aniline;Fast Red ITR Base;Azoic Diazo No.42;Metanilamide, N1,N1-diethyl-4-methoxy-;Red ITR base;N1,N1-Diethyl-4-methoxymetanilamide;3-Amino-N,N-diethyl-4-methoxybenzenesulfonamide;Benzenesulfonamide, 3-amino-N,N-diethyl-4-methoxy-;2-Methoxy-5-(diethylaminosulfonyl)aniline;Orle Base Fast Red ITR;Brentamine Fast Red ITR Base;2-Methoxyaniline-5-sulfonic acid diethylamide;EINECS 202-575-5;MFCD00009045
Molecular Formula:C11H18N2O3S
Molecular Weight:258.337
HS Code:29261000
Physical and Chemical Properties:
Melting point:102-105°C
Boiling point:410.6±55.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.547
PSA:81.01000
Exact Mass:258.103821
LogP:1.65
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1093 3/PG 1
Packing Group:I
Contact us for information like 2-Methoxy-5-(diethylsulfamoyl)aniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00009045 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Amino-N,N-diethyl-4-methoxybenzenesulfonamide Use and application,3-Amino-N,N-diethyl-4-methoxybenzenesulfonamide technical grade,usp/ep/jp grade.
Related News: It’s official. Nearly two years after the FDA granted conditional approval to Merck’s Keytruda and Eisai’s Lenvima for endometrial cancer, the U.S. regulator has blessed the combination therapy, with no strings attached. silver diamido phosphate manufacturers François-Henri Boissel, CEO of NOVA, commented: “Grégoire is an industry trail blazer with over two decades of experience in innovation, product strategy and digital entrepreneurship. μ-thioldiborane(6) suppliers During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031. Alanine, N-(1-oxopropyl)- vendor & factory During an investor event last month, Walmsley laid out her blueprint for the new GSK. It features a 5% average sales growth rate in the next five years, leading to total sales of £33 billion ($46 billion) by 2031.,By integrating biocatalysis into ongoing and newly launched projects, Wavelength Pharmaceuticals has shown that it is possible to reduce overall costs by as much as 30%.
